abstract |
The invention relates to the use of a gemifloxacin compound for the treatment of neurodegenerative diseases, mild cognitive impairment, cognitive deficiencies, dementia, diseases associated with ageing and pathological processes associated with age and progeria and, in particular, Alzheimer's disease, owing to the discovery of novel properties intrinsic to said compound. |